Why enGene Therapeutics Inc.’s (ENGN) Stock Is Up 8.64%
As of Monday, June 15, enGene Therapeutics Inc.’s ENGN share price has surged by 8.64%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Commentary & Analysis
Why enGene Therapeutics Inc.’s (ENGN) Stock Is Up 5.39%
As of Thursday, June 04, enGene Therapeutics Inc.’s ENGN share price has surged by 5.39%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why enGene Therapeutics Inc.’s (ENGN) Stock Is Down 7.27%
As of Monday, May 18, enGene Therapeutics Inc.’s ENGN share price has dipped by 7.27%, which has investors questioning if this is right time to buy.Jenna Brashear
Why enGene Therapeutics Inc.’s (ENGN) Stock Is Down 6.63%
As of Friday, May 15, enGene Therapeutics Inc.’s ENGN share price has dipped by 6.63%, which has investors questioning if this is right time to buy.Michael Rose
Why enGene Therapeutics Inc.’s (ENGN) Stock Is Up 5.84%
As of Thursday, May 14, enGene Therapeutics Inc.’s ENGN share price has surged by 5.84%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ENGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $121.9 | $282.4 | 23% |
|
| Shares Out (Mil) | 69.7 | 54.0 | 55% |
|
| Institutional Ownership | 98.0% | 93.1% | 77% |
|
| Float (Mil) | 32.7 | 42.2 | 38% |
|
| Beta | -0.27 | 0.94 | 3% |
|
| Avg Daily Volume (000s) | 724 | 482 | 66% |
|
| Price Change (52-week) |
(63.6%) | 59.9% | 11% |
|
| Growth | ENGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (50.7%) | (10.1%) | 7% |
|
| EPS (5yr) | 17.6% | 15.9% | 63 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (69.8%) | (15.6%) | 2% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 9 | 8 | |
| Current EPS | ($0.427) | ($1.727) | ($1.405) | |
| Month Ago EPS | ($0.427) | ($1.727) | ($1.405) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.500) | ($1.975) | ($1.994) | |
| Year/Year Chg | (1.6%) | (24.7%) | (59.6%) | |
| Financials | ENGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($127) | ($43) | 9% |
|
| EPS (TTM) | ($2.119) | ($1.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($110) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($28) | $2 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $31 | $4 | 35% |
|
| Enterprise Value (Q1) (Mil) | ($107) | $190 | 0% |
|
| Valuation | ENGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.48 | 2.84 | 8% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ENGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (44.2%) | (47.7%) | 13% |
|
| ROE | (52.6%) | (55.0%) | 15% |
|
| Liabilities to Assets | 17.0% | 29.8% | 11% |
|
| F-Score | 1 | 3 | 1% |
|
enGene Therapeutics Inc. did not pass any screens on 9/4/2026.
